Pfizer said on Thursday it will stop global development and commercialization of its hemophilia gene therapy, Beqvez, citing ...

A study by KFF found that one in four Republican parents now say they've skipped or delayed some childhood vaccines as of ...

The OCEANIC-AF trial has raised concerns about factor XI inhibitors. Should physicians still bet on this class of ...

Additional data from CheckMate 274 showed that adjuvant nivolumab benefits patients with muscle-invasive bladder cancer with ...

Pfizer may appeal to income investors, but growth prospects remain uncertain. Read why PFE stock might struggle to gain ...

According to multiple media reports on Thursday, Pfizer Inc. (NYSE:PFE) has terminated the global development and ...

Pfizer will end the global commercialisation of its haemophilia gene therapy Beqvez (fidanacogene elaparvovec) amid low ...

Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia product Beqvez. | ...

Pfizer's strong Q4 2024 results showcase growth in cancer drugs and Vyndaqel sales. Learn why PFE stock is a top pick for ...

While smokable product sales are declining slowly, sales of non-smokable products are driving growth for Altria Group. The company acquired the NJOY brand in 2023 and it's still one of just three ...

One of the largest pharmaceutical companies in North Carolina is discontinuing a treatment produced in the state.

An archived Facebook post claimed that Pfizer has released a list of side effects for COVID vaccine. The claim by the user is ...